299 related articles for article (PubMed ID: 12081594)
21. Tacrolimus/mycophenolate mofetil improved natural killer lymphocyte reconstitution one year after kidney transplant by reference to cyclosporine/azathioprine.
Vacher-Coponat H; Brunet C; Moal V; Loundou A; Bonnet E; Lyonnet L; Ravet S; Sampol-Manos E; Sampol J; Berland Y; George FD; Paul P
Transplantation; 2006 Aug; 82(4):558-66. PubMed ID: 16926601
[TBL] [Abstract][Full Text] [Related]
22. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
[TBL] [Abstract][Full Text] [Related]
23. Suppression of the humoral immune response by mycophenolate mofetil.
Smith KG; Isbel NM; Catton MG; Leydon JA; Becker GJ; Walker RG
Nephrol Dial Transplant; 1998 Jan; 13(1):160-4. PubMed ID: 9481733
[TBL] [Abstract][Full Text] [Related]
24. Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation.
Lederer SR; Friedrich N; Banas B; Welser G; Albert ED; Sitter T
Clin Transplant; 2005 Apr; 19(2):168-74. PubMed ID: 15740551
[TBL] [Abstract][Full Text] [Related]
25. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study.
Abramowicz D; Del Carmen Rial M; Vitko S; del Castillo D; Manas D; Lao M; Gafner N; Wijngaard P;
J Am Soc Nephrol; 2005 Jul; 16(7):2234-40. PubMed ID: 15917338
[TBL] [Abstract][Full Text] [Related]
26. The influence of immunosuppressive treatment on immune responsiveness in vivo in kidney transplant recipients.
van der Heyden AA; Bloemena E; Out TA; Wilmink JM; Schellekens PT; van Oers MH
Transplantation; 1989 Jul; 48(1):44-7. PubMed ID: 2665234
[TBL] [Abstract][Full Text] [Related]
27. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction.
Smak Gregoor PJ; van Gelder T; van Besouw NM; van der Mast BJ; IJzermans JN; Weimar W
Transplantation; 2000 Jul; 70(1):143-8. PubMed ID: 10919591
[TBL] [Abstract][Full Text] [Related]
28. Switch from cyclosporine A to tacrolimus in renal transplant recipients: impact on Th1, Th2, and monokine responses.
Weimer R; Melk A; Daniel V; Friemann S; Padberg W; Opelz G
Hum Immunol; 2000 Sep; 61(9):884-97. PubMed ID: 11053632
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of low-dose mycophenolate mofetil therapy for Taiwanese renal transplantation patients receiving primary cyclosporine immunosuppression.
Tsai MK; Hu RH; Lee CJ; Lee PH
J Formos Med Assoc; 2002 Sep; 101(9):616-21. PubMed ID: 12645188
[TBL] [Abstract][Full Text] [Related]
30. Reduction of ICAM-1 and LFA-1-positive leukocytes in the perivascular space of arteries under mycophenolate mofetil therapy reduces rat heart transplant vasculopathy.
Richter M; Zahn S; Richter H; Mohr FW; Olbrich HG
J Heart Lung Transplant; 2004 Dec; 23(12):1405-13. PubMed ID: 15607671
[TBL] [Abstract][Full Text] [Related]
31. Maintenance immunosuppression with mycophenolate mofetil and corticosteroids in pediatric kidney transplantation: temporary benefit but not without risk.
Cransberg K; Cornelissen M; Lilien M; Van Hoeck K; Davin JC; Nauta J
Transplantation; 2007 Apr; 83(8):1041-7. PubMed ID: 17452893
[TBL] [Abstract][Full Text] [Related]
32. Mycophenolate mofetil and reduced doses of cyclosporine in pediatric liver transplantation with chronic renal dysfunction: changes in the immune responses.
Ferraris JR; Duca P; Prigoshin N; Tambutti ML; Boldrini G; Cardoni RL; D'Agostino D
Pediatr Transplant; 2004 Oct; 8(5):454-9. PubMed ID: 15367280
[TBL] [Abstract][Full Text] [Related]
33. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.
Gonwa T; Johnson C; Ahsan N; Alfrey EJ; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Leonhardt M; Fitzsimmons WE
Transplantation; 2003 Jun; 75(12):2048-53. PubMed ID: 12829910
[TBL] [Abstract][Full Text] [Related]
34. Mycophenolate mofetil, together with cyclosporin A, prevents anti-OKT3 antibody response in kidney transplant recipients.
Broeders N; Wissing KM; Crusiaux A; Kinnaert P; Vereerstraeten P; Abramowicz D
J Am Soc Nephrol; 1998 Aug; 9(8):1521-5. PubMed ID: 9697676
[TBL] [Abstract][Full Text] [Related]
35. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
36. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury.
Ruggenenti P; Perico N; Gotti E; Cravedi P; D'Agati V; Gagliardini E; Abbate M; Gaspari F; Cattaneo D; Noris M; Casiraghi F; Todeschini M; Cugini D; Conti S; Remuzzi G
Transplantation; 2007 Oct; 84(8):956-64. PubMed ID: 17989600
[TBL] [Abstract][Full Text] [Related]
37. Mesenchymal stem cells together with mycophenolate mofetil inhibit antigen presenting cell and T cell infiltration into allogeneic heart grafts.
Eggenhofer E; Steinmann JF; Renner P; Slowik P; Piso P; Geissler EK; Schlitt HJ; Dahlke MH; Popp FC
Transpl Immunol; 2011 Apr; 24(3):157-63. PubMed ID: 21194567
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
Brunet M; Crespo M; Millán O; Serón D; Torregrosa V; Jiménez O; Moreso F; Martorell J; Grinyo JM; Oppenheimer F
Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124
[TBL] [Abstract][Full Text] [Related]
39. Formation of donor-specific human leukocyte antigen antibodies after kidney transplantation: correlation with acute rejection and tapering of immunosuppression.
van der Mast BJ; van Besouw NM; Witvliet MD; de Kuiper P; Smak Gregoor P; van Gelder T; Weimar W; Claas FH
Transplantation; 2003 Mar; 75(6):871-7. PubMed ID: 12660517
[TBL] [Abstract][Full Text] [Related]
40. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.
Bingham CO; Looney RJ; Deodhar A; Halsey N; Greenwald M; Codding C; Trzaskoma B; Martin F; Agarwal S; Kelman A
Arthritis Rheum; 2010 Jan; 62(1):64-74. PubMed ID: 20039397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
